Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients

Abstract

As a rare complication of mitoxantrone (MITOX) therapy in multiple sclerosis (MS), a therapy-related acute leukaemia (TRAL) may develop. The incidence is difficult to estimate, as frequently single cases are reported, up to now a total of eight MS patients. Here we report a new case out of 644 patients. This is a 45-year-old female patient with secondary progressive MS who developed TRAL after a total dose of 48 mg/m² MITOX. The TRAL was classified as acute myeloblastic leukaemia (AML) M4eo and showed an inversion of chromosome 16 and a partial trisomy 11. Her TRAL was treated with chemotherapy followed by allogeneic bone marrow transplantation. It responded well to the transplantation, whereas the MS symptoms initially worsened but have nearly returned to the pretransplantation level. This report brings the currently published frequency of MITOX-associated TRAL in MS therapy to five in a total of 2336 treated MS patients, representing an incidence of 0.21%.

Keywords

leukaemia mitoxantrone multiple sclerosis

Get full access to this article

View all access options for this article.

References

Pedersen-Bjergaard J , Philip P.

Two different classes of therapy-related and de-novo acute myeloid leukemia?

Cancer Genet Cytogenet 1991; 55: 119-124 .

Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs . Biochim Biophys Acta 1998; 1400: 233-255 .

Linassier C , Barin C , Calais G , Letortorec S , Bremond JL , Delain M et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy . Ann Oncol 2000; 11: 1289-1294 .

Hartung HP , Gonsette R , Konig N , Kwiecinski H , Guseo A , Morrissey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial . Lancet 2002; 360: 2018-2025 .

Vicari AM , Ciceri F , Folli F , Lanzi R , Colombo B , Comi G et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis . Leukemia 1998; 12: 441-442 .

Radu TD , Marc D , Herve V. Acute myeloid leukaemia (AML) induced by mitoxantrone . Mult Scler 2002; 8: P342-P342, S127-S127 .

Ghalie RG , Mauch E , Edan G , Hartung HP , Gonsette RE , Eisenmann S et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis . Mult Scler 2002; 8: 441-445 .

Heesen C , Bruegmann M , Gbdamosi J , Koch E , Monch A , Buhmann C. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone . Mult Scler 2003; 9: 213-214 .

Brassat D , Recher C , Waubant E , Le Page E , Rigal-Huguet F , Laurent G et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS . Neurology 2002; 59: 954-955 .

10.

Cattaneo C , Almici C , Borlenghi E , Motta M , Rossi G. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis . Leukemia 2003; 17: 985-986 .

11.

Goodkin DE. Therapy-related leukaemia in mitoxantrone treated patients . Mult Scler 2003; 9: 426-426 .

12.

Delisse B , de Seze J , Mackowiak A , N’Kendjuo JB , Verier A , Derepeer O et al. Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis . Mult Scler 2004; 10: 92-92 .

13.

Greer JP , Foerster J , Lukens JN , Rodgers GM , Paraskevas F , Glader BE eds. Wintrobe’s clinical hematology, eleventh edition. Philadelphia, PA: Lippincott Williams & Wilkins , 2003.

14.

Martinez-Climent JA , Comes AM , Vizcarra E , Reshmi S , Benet I , Marugan I et al. Variant three-way translocation of inversion 16 in AML-M4Eo confirmed by fluorescence in situ hybridization analysis . Cancer Genet Cytogenet 1999; 110: 111-114 .